Effects of Water-Soluble Ganoderma lucidum Polysaccharides on the Immune Functions of Patients with Advanced Lung Cancer
Authors:
- 1 June 2005
- journal article
- research article
- Published by SAGE Publications in Journal of Medicinal Food
- Vol. 8 (2) , 159-168
Abstract
Preclinical studies have established that the polysaccharide fractions of Ganoderma lucidum have potential antitumor activity. Recent clinical studies have demonstrated that G. lucidum polysaccharides enhance host immune functions [e.g., enhanced natural killer (NK) cell activity] in patients with advanced solid tumors, although an objective response was not observed. This open-label study aimed to evaluate the effects of water-soluble G. lucidum polysaccharides (Ganopoly®, Encore International Corp., Auckland, New Zealand) on immune functions in patients with advanced lung cancer. Thirty-six patients were enrolled and treated with 5.4 g/day Ganopoly for 12 weeks. In the 30 cancer patients who completed the trial, treatment with Ganopoly did not significantly alter the mean mitogenic reactivity to phytohemagglutinin, mean counts of CD3, CD4, CD8, and CD56, mean plasma concentrations of interleukin (IL)-2, IL-6, and interferon (IFN)-γ, or NK activity in the patients, but the results were significantly variable. However, some cancer patients demonstrated markedly modulated immune functions. The changes in IL-1 were correlated with those for IL-6, IFN-γ, CD3, CD8, and NK activity (P < .05), and IL-2 changes were correlated with those for IL-6, CD8, and NK activity. The results suggest that subgroups of cancer patients might be responsive to Ganopoly in combination with chemotherapy/radiotherapy. Further studies are needed to explore the efficacy and safety of Ganopoly used alone or in combination with chemotherapy/radiotherapy in lung cancer patients.Keywords
This publication has 42 references indexed in Scilit:
- Antitumor Activity and Underlying Mechanisms of Ganopoly, The Refined Polysaccharides Extracted from Ganoderma Lucidum, in MiceImmunological Investigations, 2005
- Ganoderma lucidum(‘Lingzhi’), a Chinese medicinal mushroom: biomarker responses in a controlled human supplementation studyBritish Journal of Nutrition, 2004
- Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancerLung Cancer, 2002
- A Phase I/II Study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. Extract (Ganopofy) in Patients with Advanced CancerInternational Journal of Medicinal Mushrooms, 2002
- Ligand Binding to the (1 → 3)-β-D-Glucan Receptor Stimulates NFκB Activation, but Not Apoptosis in U937 CellsBiochemical and Biophysical Research Communications, 1998
- The anti‐tumor effect of Ganoderma Lucidum is mediated by cytokines released from activated macrophages and T lymphocytesInternational Journal of Cancer, 1997
- Antitumour activity of Ganoderma lucidum, an edible mushroom, on intraperitoneally implanted lewis lung carcinoma in synergenic micePhytotherapy Research, 1992
- Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganoderma lucidum.Chemical and Pharmaceutical Bulletin, 1981
- Antitumor Polysaccharides from Some Polyporaceae, Ganoderma applanatum (PERS.) PAT and Phellinus linteus (BERK. et CURT) AOSHIMAChemical and Pharmaceutical Bulletin, 1971
- The use of the nitrogen mustards in the palliative treatment of carcinoma.With particular reference to bronchogenic carcinomaCancer, 1948